{"id":77636,"date":"2024-03-12T16:14:14","date_gmt":"2024-03-12T21:14:14","guid":{"rendered":"https:\/\/equitynewsreport.com\/natures-sunshine-products-reports-q4-earnings-and-revenue-beat\/"},"modified":"2024-03-12T16:14:14","modified_gmt":"2024-03-12T21:14:14","slug":"natures-sunshine-products-reports-q4-earnings-and-revenue-beat","status":"publish","type":"post","link":"https:\/\/equitynewsreport.com\/h\/natures-sunshine-products-reports-q4-earnings-and-revenue-beat\/","title":{"rendered":"Nature’s Sunshine Products reports Q4 earnings and revenue beat"},"content":{"rendered":"
\n
\n\"Nature's
\n\u00a9 Reuters. <\/span>
\n<\/i>\n<\/div>\n

LEHI, Utah – Nature’s Sunshine Products, Inc. (NASDAQ:NATR), a prominent health and wellness company specializing in high-quality herbal and nutritional products, has outperformed analysts’ expectations for the fourth quarter adjusted earnings per share (EPS).<\/p>\n

The company reported an adjusted EPS of $0.45, significantly higher than the analyst estimate of $0.15. However, the revenue for the quarter was slightly below the consensus, with the company posting $108.9 million against the expected $111.1 million.<\/p>\n

The fourth quarter results marked a robust period for Nature’s Sunshine, with a notable 6% increase in net sales compared to the same quarter last year, which stood at $102.7 million. This growth is even more impressive considering the constant currency net sales increase of 5.6%. The company’s GAAP net income saw a substantial rise to $9 million, up from $2 million in the prior year’s quarter, reflecting a more than threefold increase. Adjusted EBITDA also grew by 21%, reaching $9.7 million compared to $8.0 million in the year-ago quarter.<\/p>\n

CEO Terrence Moorehead expressed satisfaction with the company’s performance, attributing the strong results to double-digit sales growth in North America and effective gross margin initiatives that are on track to achieve or surpass a $10 million savings goal in 2024. Moorehead highlighted the company’s ability to execute high-level sales and cost optimization strategies, which have contributed to an increase in operating cash flow and positioned the company for continued profitable growth and shareholder value expansion.<\/p>\n

Looking ahead to the full year 2024, Nature’s Sunshine anticipates net sales to range between $455 million and $480 million, with the midpoint of this guidance slightly below the analyst consensus of $464.3 million. The company’s adjusted EBITDA forecast for the year is set to range between $42 million and $48 million.<\/p>\n

Nature’s Sunshine’s balance sheet remains strong, ending the year with $82.4 million in cash and cash equivalents and no outstanding debt. The company’s commitment to shareholder returns was evident in the repurchase of 424,000 shares at a total cost of $6.4 million during the year.<\/p>\n

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u00a9 Reuters. LEHI, Utah – Nature’s Sunshine Products, Inc. (NASDAQ:NATR), a prominent health and wellness company specializing in high-quality herbal and nutritional products, has outperformed analysts’ expectations for the fourth quarter adjusted earnings per share (EPS). The company reported an adjusted EPS of $0.45, significantly higher than the analyst estimate of $0.15. However, the revenue for the quarter was slightly below the consensus, with the company posting $108.9 million against the expected $111.1 million. The fourth quarter results marked a robust period for Nature’s Sunshine, with a notable 6% increase in net sales compared to the same quarter last year, […]<\/p>\n","protected":false},"author":5,"featured_media":77637,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[50,48,49,3],"tags":[],"_links":{"self":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/posts\/77636"}],"collection":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/comments?post=77636"}],"version-history":[{"count":0,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/posts\/77636\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/media\/77637"}],"wp:attachment":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/media?parent=77636"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/categories?post=77636"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/tags?post=77636"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}